947686-09-1

Basic information

• Product Name: Duloxetine IMpurity A
• Synonyms: N-Methyl-N-[(3S)-3-(1-naphthalenyloxy)-3-(2-thienyl)propyl]carbaMic Acid Phenyl Ester;phenyl (S)-methyl(3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl)carbamate;Duloxetine IMpurity A;Duloxetine Phenyl CarbaMate
• CAS NO: 947686-09-1
• Molecular Formula: C₂₅H₂₃NO₃S
• Molecular Weight: 417.52002
• Product Categories: Aromatics;Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 947686-09-1.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 589.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.237±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Dichloromethane (Slightly), DMSO (Slightly)
• PKA: -1.75±0.70(Predicted)
• CAS DataBase Reference: Duloxetine IMpurity A(CAS DataBase Reference)
• NIST Chemistry Reference: Duloxetine IMpurity A(947686-09-1)
• EPA Substance Registry System: Duloxetine IMpurity A(947686-09-1)

Safety Data

• Hazardous Substances Data: 947686-09-1(Hazardous Substances Data)

Usage

Uses

Duloxetine Phenyl Carbamate is a degradation product of Duloxetine (D721000). Duloxetine impurity A.

Upstream product

• 321-38-0 1-Fluoronaphthalene 
• 132335-44-5 (S)-3-dimethylamino-1-(2-thienyl)propan-1-ol 
• 88-15-3 2-Acetylthiophene 
• 5424-47-5 3-(dimethylamino)-1-(thiophen-2-yl)propan-1-one hydrochloride 
• 132335-47-8 (S)-N,N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine oxalate 
• 13636-02-7 3-(N,N-dimethylamino)-1-(thien-2-yl)propan-1-ol 
• 161005-84-1 (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, phosphoric acid salt 
• 1885-14-9 phenyl chloroformate 
• 132335-46-7 N-methyl-(S)-duloxetine 
• 116817-12-0 (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate 

Downstream Products

• 136434-34-9 duloxetine hydrochloride 
• 116539-58-3 Duloxetine 

Relevant articles and documents

Preparation method of S-(+)duloxetine hydrochloride intermediate

The invention discloses a preparation method of a compound of a formula B (shown in the description). The preparation method comprises the steps of dissolving a compound of a formula A (shown in the description) in a solvent, and reacting under the effect of a reducing agent. Furthermore, the ee value of the compound of the formula B obtained by reducing in the presence of a complex, namely ferrocene, is over 98%. The preparation method provided by the invention is simple and feasible, the resolution or the chiral catalysis induction is not required, the product yield and the chiral purity arehigh, and the preparation method is suitable for the industrial production of S-(+)duloxetine hydrochloride intermediate.

IMPROVED PROCESS FOR THE PREPARATION OF DULOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT

The present invention relates to an improved process for racemizing one of the enantiomers, or an enantiomerically enriched mixture, of an optically active compound (S)-N, N-dimethyl-3-(2-thienyl)-3-hydroxypropanamine, a key intermediate used for the preparation of (S)-N-methyl-3-(1-naphthalenyloxy)-3-(2- thienyl) propanamine (duloxetine) or its hydrochloride salt. Moreover, the present invention also relates to an improved process for the preparation of (S)-N-methyl-3- (1-naphthalenyloxy)-3-(2-thienyl) propanamine (duloxetine) or its hydrochloride salt having low content of undesired R-isomer and chiral purity not less than 99%.

AN IMPROVED PROCESS FOR THE PREPARATION OF DULOXETINE AND SALTS THEREOF

The present invention relates to improved process for the preparation of Duloxetine of formula (I) and salts thereof wherein said improvement takes place in step of condensation.